{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:28:07Z","timestamp":1792704487011,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T00:00:00Z","timestamp":1534204800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41409-018-0281-7","type":"journal-article","created":{"date-parts":[[2018,8,8]],"date-time":"2018-08-08T13:51:03Z","timestamp":1533736263000},"page":"448-457","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Maximal concentration of intravenous busulfan as a determinant of veno-occlusive disease: a pharmacokinetic-pharmacodynamic analysis in 293 hematopoietic stem cell transplanted children"],"prefix":"10.1038","volume":"54","author":[{"given":"Micha\u00ebl","family":"Philippe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Neely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Rushing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Bleyzac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,14]]},"reference":[{"key":"281_CR1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","volume":"309","author":"GW Santos","year":"1983","unstructured":"Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med. 1983;309:1347\u201353.","journal-title":"N Engl J Med"},{"key":"281_CR2","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1046\/j.1365-2141.2001.03044.x","volume":"114","author":"US Schuler","year":"2001","unstructured":"Schuler US, Renner UD, Kroschinsky F, Johne C, Jenke A, Naumann R, et al. Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol. 2001;114:944\u201350.","journal-title":"Br J Haematol"},{"key":"281_CR3","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1038\/bmt.2008.54","volume":"41","author":"A Cohen","year":"2008","unstructured":"Cohen A, B\u00e9k\u00e1ssy AN, Gaiero A, Faraci M, Zecca S, Tichelli A, et al. Endocrinological late complications after hematopoietic SCT in children. Bone Marrow Transplant. 2008;41:S43\u201348.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR4","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1038\/bmt.2008.55","volume":"41","author":"M Faraci","year":"2008","unstructured":"Faraci M, B\u00e9k\u00e1ssy AN, De Fazio V, Tichelli A, Dini G. EBMT Paediatric and Late Effects Working Parties. Non-endocrine late complications in children after allogeneic haematopoietic SCT. Bone Marrow Transplant. 2008;41:S49\u201357.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR5","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/sj.bmt.1703612","volume":"30","author":"JS McCune","year":"2002","unstructured":"McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002;30:167\u201373.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR6","first-page":"31","volume":"16","author":"JT Slattery","year":"1995","unstructured":"Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant. 1995;16:31\u201342.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR7","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","volume":"3","author":"IH Bartelink","year":"2016","unstructured":"Bartelink IH, Lalmohamed A, van Reij EML, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3:e526\u201336.","journal-title":"Lancet Haematol"},{"key":"281_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.4065\/78.5.589","volume":"78","author":"S Kumar","year":"2003","unstructured":"Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc. 2003;78:589\u201398.","journal-title":"Mayo Clin Proc"},{"key":"281_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bbmt.2009.08.024","volume":"16","author":"JA Coppell","year":"2010","unstructured":"Coppell JA, Richardson PG, Soiffer R, Martin PL, Kernan NA, Chen A, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157\u201368.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR10","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(11)61938-7","volume":"379","author":"S Corbacioglu","year":"2012","unstructured":"Corbacioglu S, Cesaro S, Faraci M, Valteau-Couanet D, Gruhn B, Rovelli A, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379:1301\u20139.","journal-title":"Lancet"},{"key":"281_CR11","first-page":"225","volume":"17","author":"SP Dix","year":"1996","unstructured":"Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant. 1996;17:225\u201330.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00694339","volume":"25","author":"LB Grochow","year":"1989","unstructured":"Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989;25:55\u201361.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"281_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.2165\/00003088-200039020-00005","volume":"39","author":"Jeannine S. McCune","year":"2000","unstructured":"McCune JS et al. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet 2000; 39:155\u201365. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/?term=Plasma+concentration+monitoring+of+busulfan%3A+does+it+improve+clinical+outcome%3F+Clin+Pharmacokinet.+2000 . Accessed 28 Sep 2017.","journal-title":"Clinical Pharmacokinetics"},{"key":"281_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.bbmt.2008.11.022","volume":"15","author":"IH Bartelink","year":"2009","unstructured":"Bartelink IH, Bredius RGM, Belitser SV, Suttorp MM, Bierings M, Knibbe CAJ, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:231\u201341.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00280-007-0455-2","volume":"61","author":"G Vassal","year":"2008","unstructured":"Vassal G, Michel G, Esp\u00e9rou H, Gentet JC, Valteau-Couanet D, Doz F, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol. 2008;61:113\u201323.","journal-title":"Cancer Chemother Pharmacol"},{"key":"281_CR16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","volume":"14","author":"M Geddes","year":"2008","unstructured":"Geddes M, Kangarloo SB, Naveed F, Quinlan D, Chaudhry MA, Stewart D, et al. High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant. 2008;14:220\u20138.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/pbc.22959","volume":"58","author":"G Michel","year":"2012","unstructured":"Michel G, Valteau-Couanet D, Gentet J-C, Esperou H, Soci\u00e9 G, M\u00e9chinaud F, et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer. 2012;58:90\u201397.","journal-title":"Pediatr Blood Cancer"},{"key":"281_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/FTD.0000000000000276","volume":"38","author":"M Neely","year":"2016","unstructured":"Neely M, Philippe M, Rushing T, Fu X, van Guilder M, Bayard D, et al. Accurately achieving target busulfan exposure in children and adolescents with very limited sampling and the BestDose software. Ther Drug Monit. 2016;38:332\u201342.","journal-title":"Ther Drug Monit"},{"key":"281_CR19","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","volume":"34","author":"MN Neely","year":"2012","unstructured":"Neely MN, van Guilder MG, Yamada WM, Schumitzky A, Jelliffe RW. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34:467\u201376.","journal-title":"Ther Drug Monit"},{"key":"281_CR20","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s40262-016-0448-6","volume":"56","author":"M Philippe","year":"2017","unstructured":"Philippe M, Neely M, Bertrand Y, Bleyzac N, Goutelle S. A nonparametric method to optimize initial drug dosing and attainment of a target exposure interval: concepts and application to busulfan in pediatrics. Clin Pharmacokinet. 2017;56:435\u201347.","journal-title":"Clin Pharmacokinet"},{"key":"281_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","volume":"118","author":"GB McDonald","year":"1993","unstructured":"McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med. 1993;118:255\u201367.","journal-title":"Ann Intern Med"},{"key":"281_CR22","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood.V85.11.3005.bloodjournal85113005","volume":"85","author":"SI Bearman","year":"1995","unstructured":"Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood. 1995;85:3005\u201320.","journal-title":"Blood"},{"key":"281_CR23","unstructured":"R Development Core Team (2005). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0. http:\/\/www.R-project.org ."},{"key":"281_CR24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1399-3046.2011.01529.x","volume":"15","author":"R Mal\u00e4r","year":"2011","unstructured":"Mal\u00e4r R, Sj\u00f6\u00f6 F, Rentsch K, Hassan M, G\u00fcng\u00f6r T. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr Transplant. 2011;15:580\u20138.","journal-title":"Pediatr Transplant"},{"key":"281_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.12659\/AOT.889933","volume":"19","author":"H Tesfaye","year":"2014","unstructured":"Tesfaye H, Branova R, Klapkova E, Prusa R, Janeckova D, Riha P, et al. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children. Ann Transplant. 2014;19:214\u201324.","journal-title":"Ann Transplant"},{"key":"281_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.bbmt.2006.10.026","volume":"13","author":"T Schechter","year":"2007","unstructured":"Schechter T, Finkelstein Y, Doyle J, Verjee Z, Moretti M, Koren G, et al. Pharmacokinetic disposition and clinical outcomes in infants and children receiving intravenous busulfan for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:307\u201314.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR27","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/petr.12236","volume":"18","author":"Y Okamoto","year":"2014","unstructured":"Okamoto Y, Nagatoshi Y, Kosaka Y, Kikuchi A, Kato S, Kigasawa H, et al. Prospective pharmacokinetic study of intravenous busulfan in hematopoietic stem cell transplantation in 25 children. Pediatr Transplant. 2014;18:294\u2013301.","journal-title":"Pediatr Transplant"},{"key":"281_CR28","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/FTD.0b013e3182a04fc7","volume":"36","author":"M Ansari","year":"2014","unstructured":"Ansari M, Th\u00e9oret Y, Rezgui MA, Peters C, Mezziani S, Desjean C, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematopoietic stem cell transplantation. Ther Drug Monit. 2014;36:93\u201399.","journal-title":"Ther Drug Monit"},{"key":"281_CR29","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.bbagen.2005.10.012","volume":"1760","author":"MB Wolf","year":"2006","unstructured":"Wolf MB, Baynes JW. The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction. Biochim Biophys Acta. 2006;1760:267\u201371.","journal-title":"Biochim Biophys Acta"},{"key":"281_CR30","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/j.transproceed.2004.05.073","volume":"36","author":"F Mercanoglu","year":"2004","unstructured":"Mercanoglu F, Turkmen A, Kocaman O, Pinarbasi B, Dursun M, Selcukbiricik F, et al. Endothelial dysfunction in renal transplant patients is closely related to serum cyclosporine levels. Transplant Proc. 2004;36:1357\u201360.","journal-title":"Transplant Proc"},{"key":"281_CR31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","volume":"8","author":"JA Russell","year":"2002","unstructured":"Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C, et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant. 2002;8:468\u201376.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR32","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","volume":"14","author":"BS Andersson","year":"2008","unstructured":"Andersson BS, de Lima M, Thall PF, Wang X, Couriel D, Korbling M, et al. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS. Biol Blood Marrow Transplant. 2008;14:672\u201384.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/sj.bmt.1705770","volume":"40","author":"YS Chae","year":"2007","unstructured":"Chae YS, Sohn SK, Kim JG, Cho YY, Moon JH, Shin HJ, et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2. Bone Marrow Transplant. 2007;40:541\u20137.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR34","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1756-8722-6-15","volume":"6","author":"H Liu","year":"2013","unstructured":"Liu H, Zhai X, Song Z, Sun J, Xiao Y, Nie D, et al. Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study. J Hematol Oncol. 2013;6:15.","journal-title":"J Hematol Oncol"},{"key":"281_CR35","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.bmt.1704446","volume":"33","author":"L Nguyen","year":"2004","unstructured":"Nguyen L, Fuller D, Lennon S, Leger F, Puozzo CIV. busulfan in pediatrics: a novel dosing to improve safety\/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004;33:979\u201387.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR36","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.bbmt.2007.06.005","volume":"13","author":"SG Ryu","year":"2007","unstructured":"Ryu S-G, Lee J-H, Choi S-J, Lee J-H, Lee Y-S, Seol M, et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13:1095\u2013105.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR37","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","volume":"104","author":"M Lima de","year":"2004","unstructured":"de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R, et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. 2004;104:857\u201364.","journal-title":"Blood"},{"key":"281_CR38","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1016\/j.bbmt.2007.03.003","volume":"13","author":"JA Russell","year":"2007","unstructured":"Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA, et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant. 2007;13:814\u201321.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR39","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/bmt.2010.190","volume":"46","author":"J Pidala","year":"2011","unstructured":"Pidala J, Kim J, Anasetti C, Kharfan-Dabaja MA, Field T, Perkins J, et al. Targeted i.v. BU and fludarabine (t-i.v. BU\/Flu) provides effective control of AML in adults with reduced toxicity. Bone Marrow Transplant. 2011;46:641\u20139.","journal-title":"Bone Marrow Transplant"},{"key":"281_CR40","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.bbmt.2011.12.584","volume":"18","author":"JB Perkins","year":"2012","unstructured":"Perkins JB, Kim J, Anasetti C, Fernandez HF, Perez LE, Ayala E, et al. Maximally tolerated busulfan systemic exposure in combination with fludarabine as conditioning before allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012;18:1099\u2013107.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR41","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR42","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M, et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2009;15:367\u20139.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.bbmt.2007.09.015","volume":"14","author":"IH Bartelink","year":"2008","unstructured":"Bartelink IH, Bredius RGM, Ververs TT, Raphael MF, Kesteren C, van, Bierings M, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14:88\u201398.","journal-title":"Biol Blood Marrow Transplant"},{"key":"281_CR44","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/MPH.0b013e3182431e1b","volume":"34","author":"M Gonz\u00e1lez-Vicent","year":"2012","unstructured":"Gonz\u00e1lez-Vicent M, Molina B, P\u00e9rez A, D\u00edaz MA. Once-daily intravenous busulfan for 47 pediatric patients undergoing autologous hematopoietic stem cell transplantation: A Single Center Study. J Pediatr Hematol Oncol. 2012;34:180.","journal-title":"J Pediatr Hematol Oncol"},{"key":"281_CR45","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1097\/01.cad.0000231482.15277.48","volume":"17","author":"J Zwaveling","year":"2006","unstructured":"Zwaveling J, den Hartigh J, Lankester AC, Guchelaar H-J, Egeler RM, Bredius RG, et al. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Anticancer Drugs. 2006;17:1099\u2013105.","journal-title":"Anticancer Drugs"},{"key":"281_CR46","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/sj.bmt.1703047","volume":"27","author":"EA Copelan","year":"2001","unstructured":"Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD, et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant. 2001;27:1121\u20134.","journal-title":"Bone Marrow Transplant"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0281-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-018-0281-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T01:23:58Z","timestamp":1720488238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-018-0281-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,14]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["281"],"URL":"https:\/\/doi.org\/10.1038\/s41409-018-0281-7","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,14]]},"assertion":[{"value":"21 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}